Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.jhep.2020.09.024
DC FieldValue
dc.titleOutcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study
dc.contributor.authorMarjot, Thomas
dc.contributor.authorMoon, Andrew M.
dc.contributor.authorCook, Jonathan A.
dc.contributor.authorAbd-Elsalam, Sherief
dc.contributor.authorAloman, Costica
dc.contributor.authorArmstrong, Matthew J.
dc.contributor.authorPose, Elisa
dc.contributor.authorBrenner, Erica J.
dc.contributor.authorCargill, Tamsin
dc.contributor.authorCatana, Maria-Andreea
dc.contributor.authorDhanasekaran, Renumathy
dc.contributor.authorEshraghian, Ahad
dc.contributor.authorGarcía-Juárez, I.
dc.contributor.authorGill, Upkar S.
dc.contributor.authorJones, Patricia D.
dc.contributor.authorKennedy, James
dc.contributor.authorMarshall, Aileen
dc.contributor.authorMatthews, Charmaine
dc.contributor.authorMells, George
dc.contributor.authorMercer, Carolyn
dc.contributor.authorPerumalswami, Ponni, V
dc.contributor.authorAvitabile, Emma
dc.contributor.authorQi, Xialong
dc.contributor.authorSu, Feng
dc.contributor.authorUfere, Nneka N.
dc.contributor.authorWong, Yu Jun
dc.contributor.authorZheng, Ming-Hua
dc.contributor.authorBarnes, Eleanor
dc.contributor.authorBarritt, Alfred S.
dc.contributor.authorWebb, Gwilym J.
dc.date.accessioned2022-10-12T08:17:05Z
dc.date.available2022-10-12T08:17:05Z
dc.date.issued2021-03-01
dc.identifier.citationMarjot, Thomas, Moon, Andrew M., Cook, Jonathan A., Abd-Elsalam, Sherief, Aloman, Costica, Armstrong, Matthew J., Pose, Elisa, Brenner, Erica J., Cargill, Tamsin, Catana, Maria-Andreea, Dhanasekaran, Renumathy, Eshraghian, Ahad, García-Juárez, I., Gill, Upkar S., Jones, Patricia D., Kennedy, James, Marshall, Aileen, Matthews, Charmaine, Mells, George, Mercer, Carolyn, Perumalswami, Ponni, V, Avitabile, Emma, Qi, Xialong, Su, Feng, Ufere, Nneka N., Wong, Yu Jun, Zheng, Ming-Hua, Barnes, Eleanor, Barritt, Alfred S., Webb, Gwilym J. (2021-03-01). Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study. Journal of Hepatology 74 (3) : 567-577. ScholarBank@NUS Repository. https://doi.org/10.1016/j.jhep.2020.09.024
dc.identifier.issn0168-8278
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/232620
dc.description.abstractBackground & Aims: Chronic liver disease (CLD) and cirrhosis are associated with immune dysregulation, leading to concerns that affected patients may be at risk of adverse outcomes following SARS-CoV-2 infection. We aimed to determine the impact of COVID-19 on patients with pre-existing liver disease, which currently remains ill-defined. Methods: Between 25th March and 8th July 2020, data on 745 patients with CLD and SARS-CoV-2 (including 386 with and 359 without cirrhosis) were collected by 2 international registries and compared to data on non-CLD patients with SARS-CoV-2 from a UK hospital network. Results: Mortality was 32% in patients with cirrhosis compared to 8% in those without (p <0.001). Mortality in patients with cirrhosis increased according to Child-Pugh class (A [19%], B [35%], C [51%]) and the main cause of death was from respiratory failure (71%). After adjusting for baseline characteristics, factors associated with death in the total CLD cohort were age (odds ratio [OR] 1.02; 1.01–1.04), Child-Pugh A (OR 1.90; 1.03–3.52), B (OR 4.14; 2.4–7.65), or C (OR 9.32; 4.80–18.08) cirrhosis and alcohol-related liver disease (OR 1.79; 1.03–3.13). Compared to patients without CLD (n = 620), propensity-score-matched analysis revealed significant increases in mortality in those with Child-Pugh B (+20.0% [8.8%–31.3%]) and C (+38.1% [27.1%–49.2%]) cirrhosis. Acute hepatic decompensation occurred in 46% of patients with cirrhosis, of whom 21% had no respiratory symptoms. Half of those with hepatic decompensation had acute-on-chronic liver failure. Conclusions: In the largest such cohort to date, we demonstrate that baseline liver disease stage and alcohol-related liver disease are independent risk factors for death from COVID-19. These data have important implications for the risk stratification of patients with CLD across the globe during the COVID-19 pandemic. Lay summary: This international registry study demonstrates that patients with cirrhosis are at increased risk of death from COVID-19. Mortality from COVID-19 was particularly high among patients with more advanced cirrhosis and those with alcohol-related liver disease. © 2020 European Association for the Study of the Liver
dc.publisherElsevier B.V.
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceScopus OA2021
dc.subjectAcute-on-chronic liver failure
dc.subjectChronic liver disease
dc.subjectCirrhosis
dc.subjectCOVID-19
dc.subjectSARS-CoV-2
dc.typeArticle
dc.contributor.departmentDEPT OF MEDICINE
dc.description.doi10.1016/j.jhep.2020.09.024
dc.description.sourcetitleJournal of Hepatology
dc.description.volume74
dc.description.issue3
dc.description.page567-577
Appears in Collections:Elements
Staff Publications

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1016_j_jhep_2020_09_024.pdf780.19 kBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons